PD-L1 Based Interventions in Cancer Treatment

tibbibiyolojiozel-2-2-24kapak

Özlem AYDIN İSAKa , Umut DEMİRCİb
aAnkara Etlik City Hospital, Clinic of Medical Oncology, Ankara, Türkiye
bMemorial Ankara Hospital, Clinic of Medical Oncology, Ankara, Türkiye

Aydın İsak Ö, Demirci U. PD-L1 based interventions in cancer treatment. In: Yar Sağlam AS, ed. Innovative Approaches in Cancer Diagnosis and Treatment. 1st ed. Ankara: Türkiye Klinikleri; 2024. p.53-8.

Makale Dili: EN

ABSTRACT
Cancer is a serious health issue that leads to the death of many people every year. Despite there being over 100 known types of cancer and the development of as standardized treatments as possible for certain types of cancer, cancer is also a personal disease. The modalities used in cancer treatment include surgery, radiotherapy, chemotherapy, hormone therapy, targeted therapies, and immunotherapies that extend the life span of cancer patients with new developments every day. Immunotherapy is a treatment approach that targets fighting cancer by activating the immune system. These treatment approaches include cytokines, T cells (immune checkpoint inhibitors and co-stimulatory receptor agonists), oncolytic viruses, cellular therapies, and vaccines. Immune checkpoint inhibitors target programmed cell death 1/programmed cell death ligand 1-2 (PD-1/PD-L1/2), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), lymphocyte activation gene 3 (LAG-3), and other potential molecules. The PD-L1 inhibitors approved by the FDA include atezolizumab, avelumab, durvalumab; PD-1 inhibitors include pembrolizumab, nivolumab, dostarlimab, cemiplimab, toripalimab.

Keywords: Immunotherapy; immune checkpoint inhibitors; antineoplastic agents

Referanslar

  1. Liu C, Yang M, Zhang D, Chen M, Zhu D. Clinical cancer immunotherapy: Current progress and prospects. Front Immunol. 2022;13:961805. [Crossref]  [PubMed]  [PMC]
  2. Pan C, Liu H, Robins E, Song W, Liu D, Li Z, et al. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. J Hematol Oncol. 2020;13(1):29. [Crossref]  [PubMed]  [PMC]
  3. Søndergaard JN, van Heeringen SJ, Looman MWG, Tang C, Triantis V, Louche P, et al. Dendritic Cells Actively Limit Interleukin-10 Production Under Inflammatory Conditions via DC-SCRIPT and Dual-Specificity Phosphatase 4. Front Immunol. 2018;9:1420. [Crossref]  [PubMed]  [PMC]
  4. Davies D, Kamdar S, Woolf R, Zlatareva I, Iannitto ML, Morton C, et al. PD-1 defines a distinct, functional, tissue-adapted state in Vδ1(+) T cells with implications for cancer immunotherapy. Nat Cancer. 2024. [Crossref]  [PubMed]  [PMC]
  5. Maher VE, Fernandes LL, Weinstock C, Tang S, Agarwal S, Brave M, et al. Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody. J Clin Oncol. 2019;37(30):2730-7. [Crossref]  [PubMed]
  6. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5(12):1365-9. [Crossref]  [PubMed]
  7. Zhou YJ, Li G, Wang J, Liu M, Wang Z, Song Y, et al. PD-L1: expression regulation. Blood Sci. 2023;5(2):77-91. [Crossref]  [PubMed]  [PMC]
  8. Kornepati AVR, Vadlamudi RK, Curiel TJ. Programmed death ligand 1 signals in cancer cells. Nat Rev Cancer. 2022;22(3):174-89. [Crossref]  [PubMed]  [PMC]
  9. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521-32. [Crossref]  [PubMed]
  10. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134-44. [Crossref]  [PubMed]  [PMC]
  11. Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018;379(4):341-51. [Crossref]  [PubMed]
  12. Wang FH, Wei XL, Feng J, Li Q, Xu N, Hu XC, et al. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02). J Clin Oncol. 2021;39(7):704-12. [Crossref]  [PubMed]  [PMC]
  13. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837-46. [Crossref]  [PubMed]
  14. Kaufman HL, Russell JS, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, et al. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer. 2018;6(1):7. [Crossref]  [PubMed]  [PMC]
  15. Ko JJ, Banerji S, Blais N, Brade A, Clelland C, Schellenberg D, et al. Follow-Up Imaging Guidelines for Patients with Stage III Unresectable NSCLC: Recommendations Based on the PACIFIC Trial. Curr Oncol. 2023;30(4):3817-28. [Crossref]  [PubMed]  [PMC]
  16. Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol. 2011;11(12):852-63. [Crossref]  [PubMed]
  17. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734-6. [Crossref]  [PubMed]
  18. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol. 2015;33(17):1889-94. [Crossref]  [PubMed]  [PMC]
  19. Kisielow M, Kisielow J, Capoferri-Sollami G, Karjalainen K. Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells. Eur J Immunol. 2005;35(7):2081-8. [Crossref]  [PubMed]
  20. Grosso JF, Goldberg MV, Getnet D, Bruno TC, Yen HR, Pyle KJ, et al. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol. 2009;182(11):6659-69. [Crossref]  [PubMed]  [PMC]
  21. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20. [Crossref]  [PubMed]  [PMC]
  22. Udall M, Rizzo M, Kenny J, Doherty J, Dahm S, Robbins P, Faulkner E. PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics. Diagn Pathol. 2018;13(1):12. [Crossref]  [PubMed]  [PMC]
  23. de Ruiter EJ, Mulder FJ, Koomen BM, Speel EJ, van den Hout M, de Roest RH, et al. Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC). Mod Pathol. 2021;34(6):1125-32. [Crossref]  [PubMed]
  24. Bai Z, Zhou Y, Ye Z, Xiong J, Lan H, Wang F. Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy. Front Immunol. 2021;12:808964. [Crossref]  [PubMed]  [PMC]
  25. Chamoto K, Yaguchi T, Tajima M, Honjo T. Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1. Nat Rev Immunol. 2023;23(10):682-95. [Crossref]  [PubMed]
  26. Butterfield LH, Najjar YG. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nat Rev Immunol. 2023. [Crossref]  [PubMed]